These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8127416)

  • 1. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
    Watanobe H; Tamura T; Sasaki S; Takebe K
    Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of the growth hormone response to vasoactive intestinal peptide and gonadotropin-releasing hormone in acromegaly.
    Watanobe H; Tamura T
    Neuropeptides; 1995 Feb; 28(2):115-24. PubMed ID: 7746355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture.
    Ishibashi M; Yamaji T
    J Clin Endocrinol Metab; 1985 May; 60(5):985-93. PubMed ID: 2858494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The higher the growth hormone response to growth hormone releasing hormone the lower the response to bromocriptine and thyrotrophin releasing hormone in acromegaly.
    Smals AE; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):43-7. PubMed ID: 3115634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical response of growth hormone to peptide histidine methionine in acromegaly: comparison with the effects of thyrotropin-releasing hormone and vasoactive intestinal peptide.
    Watanobe H; Sasaki S; Sone K; Takebe K
    J Clin Endocrinol Metab; 1991 May; 72(5):982-5. PubMed ID: 1902488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone responses to the releasing hormones GHRH and GnRH and the inhibitors somatostatin and bromocriptine in TRH-responsive and non-responsive acromegalics.
    Smals AE; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
    Acta Endocrinol (Copenh); 1987 Sep; 116(1):53-8. PubMed ID: 2889308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of involvement of the cholinergic mechanism in vasoactive intestinal peptide- and peptide-histidine methionine-induced growth hormone (GH) responses in acromegaly: comparison with the GH responses to thyrotropin-releasing hormone and GH-releasing hormone.
    Watanobe H; Habu S; Nasushita R; Takebe K
    Neuropeptides; 1994 Aug; 27(2):85-90. PubMed ID: 7991070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal growth hormone responses to CB-154 and thyrotropin-releasing hormone (TRH) in patients with acromegaly.
    Hanew K; Aida M; Sasaki A; Mouri T; Yoshinaga K
    Tohoku J Exp Med; 1979 Jan; 127(1):53-62. PubMed ID: 104407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
    Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
    J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A re-evaluation of the prolactin-releasing activity of growth hormone-releasing hormone in acromegaly in vivo.
    Watanobe H; Tamura T
    Neuropeptides; 1995 Feb; 28(2):73-8. PubMed ID: 7746357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reevaluation of the I-dopa test in acromegaly: anatomo-clinical and prognostic correlations].
    De Marinis L; Mancini A; Zuppi P; Fiumara C; Iacona T; Conte G; Fabrizi ML; Valle D; Anile C; Maira G
    Minerva Chir; 1993 Nov; 48(21-22):1337-40. PubMed ID: 8152567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of growth hormone by vasoactive intestinal polypeptide in acromegaly.
    Chihara K; Kaji H; Minamitani N; Kodama H; Kita T; Goto B; Chiba T; Coy DH; Fujita T
    J Clin Endocrinol Metab; 1984 Jan; 58(1):81-6. PubMed ID: 6417157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The relationship between TSH response to TRH and GH response to dopaminergic agents in patients with acromegaly].
    Tokuyama T; Yoshinari M; Okamura K; Ikenoue H; Sato K; Kuroda T; Fujishima M
    Nihon Naibunpi Gakkai Zasshi; 1991 Feb; 67(2):65-74. PubMed ID: 1674920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A further study on the stimulatory effect of peptide histidine methionine on growth hormone secretion in acromegaly: a dose-related study and a comparison with vasoactive intestinal peptide.
    Watanobe H; Takebe K
    Neuropeptides; 1992 Oct; 23(2):115-9. PubMed ID: 1333573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
    Chang CC; Chen FW; Hsieh HC
    Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma growth hormone (GH) responses to corticotropin-releasing hormone in patients with acromegaly--the effect of dexamethasone pretreatment and the comparison with GH responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and GH-releasing hormone.
    Utsumi A; Hanew K; Sugawara A; Shimizu Y; Murakami O; Ikeda H; Yoshinaga K
    J Endocrinol Invest; 1992 Mar; 15(3):167-71. PubMed ID: 1624675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulatory and inhibitory effects of neuropeptide Y on growth hormone secretion in acromegaly in vivo.
    Watanobe H; Tamura T
    Neuropeptides; 1997 Feb; 31(1):29-34. PubMed ID: 9574834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.